An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.
Fiedler W, Mesters R, Heuser M, Ehninger G, Berdel WE, Zirrgiebel U, Robertson JD, Puchalski TA, Collins B, Jürgensmeier JM, Serve H.
Fiedler W, et al. Among authors: jurgensmeier jm.
Leuk Res. 2010 Feb;34(2):196-202. doi: 10.1016/j.leukres.2009.07.020. Epub 2009 Aug 11.
Leuk Res. 2010.
PMID: 19674789
Clinical Trial.